Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Gilead/GlaxoSmithKline's Ambrisentan and Encysive's Thelin will challenge Actelion's Tracleer for market leadership in the treatment of pulmonary arterial hypertension (PAH).

The new Spectrum report Pulmonary Arterial Hypertension Market Offers Opportunity for New and Established Agents finds that, although the endothelin receptor antagonist (ERA) Tracleer is currently the dominant player in the PAH market, it will face increasing competition from more conveniently administered ERAs, including Ambrisentan and Thelin. Additionally, United Therapeutics' inhaled and oral versions of Remodulin, which are currently in clinical trials, have shown significant promise with few adverse effects in the treatment of PAH.

The report also finds that because only five drug classes are widely approved to treat PAH and the pathways involved in the disease yield many drug targets, a substantial opportunity remains in the world's major pharmaceutical markets for the development of novel therapies during the 2005 to 2010 study period.

"The expected growth of the PAH population, combined with improving awareness of the disease, a need for more convenient treatments, and increasing polypharmacy means there is significant room for new products in this market," said Nikhil Mehta, analyst at Decision Resources. "Additionally, the small number of prescribing physicians for PAH allows companies with smaller sales forces to be competitive in this market."

About Spectrum

Spectrum is an executive advisory service built on an extensive network of leading industry experts to deliver thought-provoking commentary and analysis of strategic business and technology issues shaping the global pharmaceutical and biotechnology markets.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com/ ) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

First Call Analyst:

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, or emarshall@dresources.com

Innovation and Premium Pricing Drive Growth in the US Dental Implant Market

View Now